<DOC>
	<DOCNO>NCT03051607</DOCNO>
	<brief_summary>Phase 3 , international , multicenter , open-label 12 month safety study .</brief_summary>
	<brief_title>A Multicenter , Open-Label Study Evaluate Safety Tolerability Tozadenant Adjunctive Therapy Levodopa-Treated Patients With Parkinson 's Disease Experiencing End Dose `` Wearing-Off ''</brief_title>
	<detailed_description>Each patient participate 62 week , include Screening Period , follow Baseline Visit open-label treatment 1 year safety Follow-up 4 week last treatment . - Screening Period : 6 week . - Open-Label Treatment Period : 52 week ( 1 year ) - Post-Treatment Safety Follow Up : 4 week .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patient understand study requirement give his/her write informed consent Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) approve consent form . Parkinson 's disease diagnosis consistent UK Parkinson 's Disease Society Brain Bank Diagnostic criterion Minimum 3 year since diagnosis . Meet Hoehn Yahr PD stage Good response levodopa Stable regimen antiPD medication Patients must take levodopacontaining antiPD medication continuously least previous 12 month Patient document minimum amount Off time . If childbearing potential ( male female ) must use acceptable method contraception Previous tozadenant study participation Current recent participation another study . Secondary atypical parkinsonism Neurosurgical intervention PD ( except DBS electrode placement perform 12 month prior screen ) Patient take apomorphine , budipine , istradefylline , tolcapone , DUOPA™/Duodopa® Treatment exclude medication Untreated uncontrolled hyperthyroidism hypothyroidism Clinically significant outofrange laboratory MMSE range Current episode major depression ( stable treatment depression permit ) . Recent suicide attempt suicidal ideation type 4 type 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) Women lactate pregnant Hypersensitivity component tozadenant excipients Abnormal finding physical neurological examination , medical history would make patient unsuitable study History hepatitis cholangitis</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Motor Fluctuations</keyword>
	<keyword>Off time</keyword>
	<keyword>On time</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>